What we do Novartis India Ltd develops, manufactures, and markets pharmaceuticals, generics, OTC, and animal health products, serving the Indian and select global markets. |
Founded in 1,947 |
Market share One of the leading global pharmaceutical companies with a strong position in Indian prescription and generics markets. |
Problem solved Provides treatments for chronic diseases, oncology, neurosciences, and healthcare needs addressing affordability and accessibility in India. |
Top clients or who we serve Healthcare professionals, hospitals, pharmacies, animal health providers; B2B and B2C segments across India and export markets. |
Key management Mr. Falin Ishwarlal Majmudar (Whole-Time Director), Ms. Shilpa Joshi (Whole-Time Director and CFO). |
Our journey and innovations Founded in 1947, merged from legacy companies, launched pioneering drugs like Glivec; strong R&D focus in neglected diseases and chronic therapies. |
Where we operate India primarily, with some revenues from other countries. |
Top products or what we offer Pharmaceuticals including oncology (Glivec), neurosciences (Exelon), pain management (Voveran), generics under Sandoz, OTC, and animal health products. |
Top brands Glivec (exclusive marketing rights), Voveran (market growth in pain management), Simulect, Certican, Myfortic in transplantation. |
Raw materials needed Active pharmaceutical ingredients, chemical intermediates sourced globally. |
Raw materials supplier Novartis Pharma AG and other approved suppliers. |
Recurring vs cyclical contribution Revenue mainly recurring from pharmaceutical sales and long-term contracts. |
Our industry position Leader in specialty and generic pharmaceuticals with focus on chronic and transplantation therapies in India. |
Financial highlights FY 2024-25 revenue ₹3,562.7 million; PAT ₹1,009 million; 6.3% revenue growth; strong margin improvement. |
Geographical revenue split India accounts for ~99% revenue; rest from other countries. |
Order book - |
Whats driving growth Chronic disease prevalence, government health initiatives (Ayushman Bharat), expanding healthcare access, innovative therapies. |
Our future plans Focus on expanding transplant and chronic therapy portfolios, strengthening market presence, and enhancing R&D and partnerships. |
Our green promise Committed to sustainable practices, CSR in health and community development, and adherence to good manufacturing norms. |
Our people and values 56 employees, culture of innovation, compliance, and patient-centric values. |
Key challenges ahead Regulatory changes, generic competition, pricing pressures, and supply chain constraints. |
Interesting facts Part of global Novartis, involved in leprosy and malaria eradication programs; launched India's first patented cancer drug Glivec. |
Risks and strategy Mitigates risks through strong compliance, diversified portfolio, strategic partnerships, and focus on innovation and efficiency. |
